Trial · NCT04650854
Results by group84
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 84
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) | Rozanolixizumab ~7 mg/kg | 78.4 | percentage of participants | ||
| Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) | Rozanolixizumab ~10 mg/kg | 94.1 | percentage of participants | ||
| Percentage of Participants With TEAEs Leading to Withdrawal of Investigational Medicinal Product (IMP) | Rozanolixizumab ~7 mg/kg | 9.8 | percentage of participants | ||
| Percentage of Participants With TEAEs Leading to Withdrawal of Investigational Medicinal Product (IMP) | Rozanolixizumab ~10 mg/kg | 16.7 | percentage of participants | ||
| Change From Baseline (Day 1) to Day 43 in Myasthenia Gravis-Activities of Daily Living (MG-ADL) Score Within One Treatment Cycle (Cycle 1, 2, and 3) | Rozanolixizumab ~7 mg/kg | Cycle 1: Treatment (Day 43) | -3.7 | Standard Deviation 3.5 | score on a scale |
| Change From Baseline (Day 1) to Day 43 in Myasthenia Gravis-Activities of Daily Living (MG-ADL) Score Within One Treatment Cycle (Cycle 1, 2, and 3) | Rozanolixizumab ~10 mg/kg | Cycle 1: Treatment (Day 43) | -3.1 | Standard Deviation 2.9 | score on a scale |
| Change From Baseline (Day 1) to Day 43 in Myasthenia Gravis-Activities of Daily Living (MG-ADL) Score Within One Treatment Cycle (Cycle 1, 2, and 3) | Rozanolixizumab ~7 mg/kg | Cycle 2: Treatment (Day 43) | -2.9 | Standard Deviation 3.1 | score on a scale |
| Change From Baseline (Day 1) to Day 43 in Myasthenia Gravis-Activities of Daily Living (MG-ADL) Score Within One Treatment Cycle (Cycle 1, 2, and 3) | Rozanolixizumab ~10 mg/kg | Cycle 2: Treatment (Day 43) | -3.8 | Standard Deviation 3.9 | score on a scale |
| Change From Baseline (Day 1) to Day 43 in Myasthenia Gravis-Activities of Daily Living (MG-ADL) Score Within One Treatment Cycle (Cycle 1, 2, and 3) | Rozanolixizumab ~7 mg/kg | Cycle 3: Treatment (Day 43) | -3.3 | Standard Deviation 2.7 | score on a scale |
| Change From Baseline (Day 1) to Day 43 in Myasthenia Gravis-Activities of Daily Living (MG-ADL) Score Within One Treatment Cycle (Cycle 1, 2, and 3) | Rozanolixizumab ~10 mg/kg | Cycle 3: Treatment (Day 43) | -3.2 | Standard Deviation 3.3 | score on a scale |
| Change From Baseline (Day 1) to Day 43 in Quantitative Myasthenia Gravis (QMG) Score Within One Treatment Cycle (Cycle 1, 2, and 3) | Rozanolixizumab ~7 mg/kg | Cycle 1: Treatment (Day 43) | -4.5 | Standard Deviation 5.0 | score on a scale |
| Change From Baseline (Day 1) to Day 43 in Quantitative Myasthenia Gravis (QMG) Score Within One Treatment Cycle (Cycle 1, 2, and 3) | Rozanolixizumab ~10 mg/kg | Cycle 1: Treatment (Day 43) | -4.1 | Standard Deviation 4.2 | score on a scale |
| Change From Baseline (Day 1) to Day 43 in Quantitative Myasthenia Gravis (QMG) Score Within One Treatment Cycle (Cycle 1, 2, and 3) | Rozanolixizumab ~7 mg/kg | Cycle 2: Treatment (Day 43) | -3.9 | Standard Deviation 4.1 | score on a scale |
| Change From Baseline (Day 1) to Day 43 in Quantitative Myasthenia Gravis (QMG) Score Within One Treatment Cycle (Cycle 1, 2, and 3) | Rozanolixizumab ~10 mg/kg | Cycle 2: Treatment (Day 43) | -4.9 | Standard Deviation 5.5 | score on a scale |
| Change From Baseline (Day 1) to Day 43 in Quantitative Myasthenia Gravis (QMG) Score Within One Treatment Cycle (Cycle 1, 2, and 3) | Rozanolixizumab ~7 mg/kg | Cycle 3: Treatment (Day 43) | -5.1 | Standard Deviation 4.8 | score on a scale |
| Change From Baseline (Day 1) to Day 43 in Quantitative Myasthenia Gravis (QMG) Score Within One Treatment Cycle (Cycle 1, 2, and 3) | Rozanolixizumab ~10 mg/kg | Cycle 3: Treatment (Day 43) | -4.2 | Standard Deviation 4.4 | score on a scale |
| Change From Baseline (Day 1) to Day 43 in Myasthenia Gravis-Composite (MG-C) Score Within One Treatment Cycle (Cycle 1, 2, and 3) | Rozanolixizumab ~7 mg/kg | Cycle 1: Treatment (Day 43) | -7.6 | Standard Deviation 7.3 | score on a scale |
| Change From Baseline (Day 1) to Day 43 in Myasthenia Gravis-Composite (MG-C) Score Within One Treatment Cycle (Cycle 1, 2, and 3) | Rozanolixizumab ~10 mg/kg | Cycle 1: Treatment (Day 43) | -4.7 | Standard Deviation 5.7 | score on a scale |
| Change From Baseline (Day 1) to Day 43 in Myasthenia Gravis-Composite (MG-C) Score Within One Treatment Cycle (Cycle 1, 2, and 3) | Rozanolixizumab ~7 mg/kg | Cycle 2: Treatment (Day 43) | -5.7 | Standard Deviation 5.4 | score on a scale |
| Change From Baseline (Day 1) to Day 43 in Myasthenia Gravis-Composite (MG-C) Score Within One Treatment Cycle (Cycle 1, 2, and 3) | Rozanolixizumab ~10 mg/kg | Cycle 2: Treatment (Day 43) | -7.5 | Standard Deviation 7.0 | score on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04650854/results